^
    Back
    Association details:
    Biomarker:PIK3CA mutation + HR negative
    Cancer:HER2 Negative Breast Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2023
    Title:

    Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.

    Published date:
    05/25/2023
    Excerpt:
    ...BYLieve study demonstrated the efficacy of ALP + ET in pts with HR+, HER2–, PIK3CA-mutated ABC...After ≥18 mo follow-up, with mature data, ALP + ET demonstrated clinical activity in BYLieve Cohorts A, B, and C. Within the trial, ALP + ET showed median OS between 20.7 mo and 29.0 mo following prior CDK4/6i, chemotherapy, or ET.
    Secondary therapy:
    Hormone Therapy
    DOI:
    10.1200/JCO.2023.41.16_suppl.1078
    Trial ID:
    BYLieve